Health
03 August 2022, 3:09 pm. 1 minute
Reuters exclusively reported UnitedHealth Group Inc, the top U.S. healthcare company by market capitalization, is struggling to sell Brazilian unit Amil due to antitrust issues and growing losses from individual health plans. After studying ways to divest Amil 10 years after acquiring it, UnitedHealth decided last month to suspend the sale process, asking for anonymity because the discussions were private.
Article Tags
Topics of Interest: Health
Type: Reuters Best
Sectors: Business & Finance
Regions: South America
Countries: BrazilUS
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Customer Impact: Important Regional Story
Sign up for email updates
I'd like to receive communications about Reuters resources, events, products, or services.
(Please note you can manage and update your preferences at any time.)
By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement.By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement. * required field
By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement. * required field
Sign up for email updates
I'd like to receive communications about Reuters resources, events, products, or services.
(Please note you can manage and update your preferences at any time.)
By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement.By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement. * required field
By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement. * required field